LivaNova PLC announced the completion of its CORE-VNS study, a real-world evidence study evaluating VNS Therapy™ in over 800 epilepsy patients worldwide. The final 36-month data validate the effectiveness of VNS Therapy for severe focal seizures in both children and adults with drug-resistant epilepsy (DRE), demonstrating early and lasting outcomes.
For children aged 4 to 18 years old, focal onset seizures with impaired awareness (FIA) motor seizures reduced by a median of 87% at 36 months. Including adults, 34% of people with FIA motor seizures reported 100% seizure reduction, with an overall median reduction of 80%. Focal to bilateral tonic-clonic (FBTC) seizures in children reduced by a median of 100% at 36 months, and 49% of all patients with FBTC seizures reported 100% seizure reduction, with an overall median reduction of 95%.
The effectiveness of VNS Therapy was observed as early as three months post-implantation and continued to improve over the three-year follow-up period, with a high patient-retention rate of 82%. These results bolster efforts to address the DRE treatment gap and increase access to care, solidifying the therapy's long-term value.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.